Puma Biotechnology, Inc. (PBYI)
Price:
5.70 USD
( - -1.90 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Vertex Pharmaceuticals Incorporated
VALUE SCORE:
8
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Aurinia Pharmaceuticals Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
NEWS
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
zacks.com
2026-02-27 13:35:21Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-26 21:37:56Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
zacks.com
2026-02-26 19:46:06Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago.
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
2026-02-26 16:05:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 4Q-2025 earnings release on Feb. 26 and followed with a conference call to review results.
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference
businesswire.com
2026-02-23 16:15:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
2026-02-12 16:07:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its fourth quarter and full year 2025 results, followed be a conference call, after the close on Feb. 26, 2026.
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving Average – What’s Next?
defenseworld.net
2026-02-10 03:55:08Puma Biotechnology, Inc. (NASDAQ: PBYI - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $5.27 and traded as high as $6.98. Puma Biotechnology shares last traded at $6.88, with a volume of 410,370 shares changing hands. Wall Street Analyst Weigh In
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2026-02-04 17:05:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the grant of inducement awards to two new hires in January 2026, as required under Nasdaq Listing Rule 5635(c)(4).
New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand
prnewswire.com
2026-01-22 05:00:00Eligible women with breast cancer in Thailand now have access to a new therapy, NERLYNX (neratinib), for the first time The launch of NERLYNX provides an
Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened
defenseworld.net
2026-01-08 03:55:05Shares of Puma Biotechnology, Inc. (NASDAQ: PBYI - Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $4.76 and traded as high as $6.11. Puma Biotechnology shares last traded at $6.09, with a volume of 394,317 shares traded. Analysts Set New Price Targets
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2026-01-07 17:15:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted to December 2025 new hires, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
businesswire.com
2025-12-22 16:10:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology was added to the Nasdaq Biotechnology Index effective after the close of trading on Dec. 19, 2025.
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
zacks.com
2025-12-17 12:31:13CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-12-02 17:15:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award.
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
zacks.com
2025-11-27 13:01:30Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
Puma Biotechnology: Step By Step In Making A Transition
seekingalpha.com
2025-11-10 06:02:04Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise.
No data to display
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
zacks.com
2026-02-27 13:35:21Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-26 21:37:56Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
zacks.com
2026-02-26 19:46:06Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago.
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
2026-02-26 16:05:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 4Q-2025 earnings release on Feb. 26 and followed with a conference call to review results.
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference
businesswire.com
2026-02-23 16:15:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
2026-02-12 16:07:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its fourth quarter and full year 2025 results, followed be a conference call, after the close on Feb. 26, 2026.
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving Average – What’s Next?
defenseworld.net
2026-02-10 03:55:08Puma Biotechnology, Inc. (NASDAQ: PBYI - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $5.27 and traded as high as $6.98. Puma Biotechnology shares last traded at $6.88, with a volume of 410,370 shares changing hands. Wall Street Analyst Weigh In
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2026-02-04 17:05:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the grant of inducement awards to two new hires in January 2026, as required under Nasdaq Listing Rule 5635(c)(4).
New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand
prnewswire.com
2026-01-22 05:00:00Eligible women with breast cancer in Thailand now have access to a new therapy, NERLYNX (neratinib), for the first time The launch of NERLYNX provides an
Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened
defenseworld.net
2026-01-08 03:55:05Shares of Puma Biotechnology, Inc. (NASDAQ: PBYI - Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $4.76 and traded as high as $6.11. Puma Biotechnology shares last traded at $6.09, with a volume of 394,317 shares traded. Analysts Set New Price Targets
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2026-01-07 17:15:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted to December 2025 new hires, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
businesswire.com
2025-12-22 16:10:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology was added to the Nasdaq Biotechnology Index effective after the close of trading on Dec. 19, 2025.
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
zacks.com
2025-12-17 12:31:13CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-12-02 17:15:00LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award.
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
zacks.com
2025-11-27 13:01:30Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
Puma Biotechnology: Step By Step In Making A Transition
seekingalpha.com
2025-11-10 06:02:04Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise.